Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Convertible Debt (2020 - 2021)

Historic Convertible Debt for Ensysce Biosciences (ENSCW) over the last 2 years, with Q4 2021 value amounting to $16.8 million.

  • Ensysce Biosciences' Convertible Debt rose 240645.82% to $16.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $16.8 million, marking a year-over-year increase of 240645.82%. This contributed to the annual value of $16.8 million for FY2021, which is 240645.82% up from last year.
  • Ensysce Biosciences' Convertible Debt amounted to $16.8 million in Q4 2021, which was up 240645.82% from $4.2 million recorded in Q3 2021.
  • Ensysce Biosciences' Convertible Debt's 5-year high stood at $16.8 million during Q4 2021, with a 5-year trough of $670262.0 in Q4 2020.